Tatjana May
General counsel, company secretary and executive vice president global legal affairs
Shire Pharmaceuticals
Tatjana May has been with Shire Pharmaceuticals, the UK’s third largest drugs group, since 2001, having spent the earlier part of her career in the prestigious surroundings of AstraZeneca, where she was assistant general counsel, and Slaughter and May. In 2008 she was also appointed chair of the corporate responsibility committee.
Sales have grown at least 15% a year in four of the past five years, with more than 30% of Shire’s 2011 revenue of $4.2bn coming from the ADHD drug Adderall XR and its successor Vyvanse. Shire has been the subject of frequent takeover speculation in the last 18 months, with rival drug companies Bayer and AstraZeneca among the many names mooted as suitors.
Law firms used: Davis Polk & Wardwell, Slaughter and May
2001-present: General counsel, company secretary and executive vice president global legal affairs, Shire Pharmaceuticals
1995-2001: Assistant general counsel, AstraZeneca